Transient transfection introduces nucleic acid into cells for a short window — typically 24 to 96 hours — without integrating it into the genome. It is the fastest way to test a construct, express a tagged protein, or run a reporter assay, and its central practical problem is that efficiency and toxicity vary enormously between cell types, constructs, and operators. A protocol that gives 90% transfection in HEK293T may give 5% in a primary neuron. There is no universal method, only methods that are optimal for a given cell and question, and optimisation is the work.
Choosing a method: three routes with different physics
The methods deliver DNA by fundamentally different mechanisms, which explains their different cell-type preferences.
- Lipid-based reagents (Lipofectamine, FuGENE, PEI) form positively charged lipoplexes that fuse with or endocytose into the plasma membrane. They are gentle, simple, and work well for adherent lines such as HEK293T, HeLa, and COS-7. Efficiency depends on the lipid:DNA ratio, the DNA concentration, and the presence of serum; most formulations require serum-free complex formation, then serum can be restored.
- Electroporation applies a transient electric field that creates pores in the membrane, driving charged nucleic acid into the cell. It is the method of choice for suspension cells, primary cells, and hard-to-transfect lines, and the only practical route for many immune cells. Nucleofection (a proprietary electroporation variant) achieves high efficiency in primary cells by combining the pulse with cell-type-specific buffers. The trade-off is that the pulse damages cells, so viability often drops and the optimal parameters are a balance between efficiency and survival.
- Calcium phosphate co-precipitation is the oldest method: DNA is mixed with calcium chloride and phosphate buffer to form a fine precipitate that cells take up by endocytosis. It is cheap, effective for some lines (notably HEK293), and produces a broad distribution of DNA copy number per cell, which is actually useful for generating stably expressing lines. Its weaknesses are sensitivity to pH and buffer freshness, variability between operators, and high toxicity in many cell types.
Optimising transfection efficiency
Every method has a small set of variables that dominate the outcome. Fixing these deliberately beats random variation.
- DNA quality: use endotoxin-free maxi-prep DNA. Endotoxin and residual protein from a miniprep reduce efficiency and increase toxicity; the difference is often larger than the difference between reagents.
- Cell density: transfect at 60–80% confluence for adherent cells. Too sparse and the cells are stressed; too dense and contact inhibition reduces uptake. Plate the day before, allow cells to recover and attach, and use consistent timing.
- DNA amount: more is not better. Beyond a threshold, efficiency plateaus and toxicity rises. Titrate DNA from 0.1 to 2 µg per well in the format you will use.
- Complex formation: for lipid reagents, incubate the lipid–DNA complex for the recommended time (usually 15–30 minutes) at room temperature in serum-free medium; over-incubation aggregates the complexes.
- Serum: serum can inhibit lipid-based delivery but also improves cell health; many protocols remove serum during complex formation and restore it afterward. Test both.
Report the conditions fully: reagent and lot, DNA amount and construct, cell density at transfection, medium composition, and the time from transfection to assay. Without these, transfection efficiency is not reproducible even within the same lab.
Validating expression from a reporter
It is tempting to assume that a plasmid "works" because the cells fluoresce. A proper validation checks the construct, the protein product, and the biological activity separately.
- Construct integrity: Sanger-sequence the full insert and the junctions, and confirm the promoter and terminator. A single base change can alter a tag's reading frame or a promoter's activity.
- Protein product: detect the tagged protein by western blot with an anti-tag antibody, checking size against prediction and confirming that the endogenous protein is not co-migrating. Note that high-level expression can cause aggregation and the formation of insoluble species that do not enter the gel.
- Localisation and function: verify the tag does not mislocalise the protein or interfere with its activity. For reporters, compare a promoter-driven reporter with a promoterless negative control and a constitutive positive control.
- Transfection control: co-transfect a constitutive reporter (e.g., Renilla or GFP) and normalise for efficiency, especially when comparing conditions or cell types.
A common failure mode is mistaking high expression for correct function. An over-expressed protein may saturate its partners, alter stoichiometry, or dominate a pathway quantitatively even when it is qualitatively normal. For interaction studies, titrate the expression level and check that the observed effect depends on the interacting surface (via a point mutant) rather than on abundance.
Transient versus stable transfection
The distinction is not just duration; it changes what can be measured and what the data mean.
- Transient expression peaks 24–72 hours after delivery and then declines as the plasmid is diluted by division and degraded. It is fast, requires no selection, and is ideal for acute experiments, overexpression, reporter assays, and testing CRISPR components. Because expression varies widely between cells, population-level averages obscure cell-to-cell heterogeneity, and single-cell methods (imaging, flow) are often more informative than bulk assays.
- Stable transfection requires selection (antibiotic resistance, fluorescence-activated sorting, or a metabolic marker) and produces a population in which the transgene is maintained, usually integrated into the genome at a random or targeted site. Stability allows long-term experiments and avoids the transfection-efficiency confound, but the integration site affects expression level and can disrupt endogenous genes, so single clones must be characterised. Expression can be silenced epigenetically over time, especially with viral promoters in stem cells.
The choice follows the question. Measuring an acute signalling response: transient. Testing a dose–response over days or establishing a model cell line: stable. Attempting a rescue of a knockout: either can work, but the rescue construct must be expressed at a level comparable to the endogenous protein, which usually means using the native promoter and a single-copy or low-copy system rather than a strong viral promoter. Over-expression rescue is a weak experiment; physiological-level rescue is the standard.
References
- Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52(2):456–467.
- Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A. 1987;84(21):7413–7417.
- Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. 1982;1(7):841–845.
- Jordan ET, Collins M, Terefe J, et al. Optimizing electroporation parameters in high throughput transfection. J Biomol Tech. 2008;19(5):328–334.
- Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995;92(16):7297–7301.
- Chicaybam L, Sodre AL, Curzio BA, Bonamino MH. An efficient low cost method for gene transfer to T lymphocytes. PLoS One. 2013;8(3):e60298.
- Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 1987;7(8):2745–2752.
- Kovesdi I, Weber B, et al. Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading. Proc Natl Acad Sci U S A. 1987;84(23):8463–8467.
- Kim TK, Eberwine JH. Mammalian cell transfection: the present and the future. Anal Bioanal Chem. 2010;397(8):3173–3178.
- Stewart MP, Sharei A, Ding X, et al. In vitro and ex vivo strategies for intracellular delivery. Nature. 2016;538(7624):183–192.